Who will benefit from antiresorptive treatment (bisphosphonates)?

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 6, 2005, Pages 965-973

  Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biophosphates; Bone mineral density; Bone treatment; Fracture risk

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID;

BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RETENTION; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LONG TERM CARE; METABOLIC BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 28644433847     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.06.009     Document Type: Review

References (32)

1. U.A. Liberman S.R. Weiss J. Broll et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group The New England Journal of Medicine 333 1995 1437-1443
2. D.M. Black S.R. Cummings D.B. Karpf et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535-1541
3. S.R. Cummings D.M. Black D.E. Thompson et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial The Journal of the American Medical Association 280 1998 2077-2082
4. H.A. Pols D. Felsenberg D.A. Hanley et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group Osteoporosis International 9 1999 461-468
5. D.M. Black D.E. Thompson D.C. Bauer et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group Journal of Clinical Endocrinology and Metabolism 85 2000 4118-4124
6. S.T. Harris N.B. Watts H.K. Genant et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group The Journal of the American Medical Association 282 1999 1344-1352
7. J.Y. Reginster H.W. Minne O.H. Sorensen et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group Osteoporosis International 11 2000 83-91
8. M.R. McClung P. Geusens P.D. Miller et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group The New England Journal of Medicine 344 2001 333-340
9. O.H. Sorensen G.M. Crawford H. Mulder et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience Bone 32 2003 120-126
10. C. Brumsen S.E. Papapoulos P. Lips et al. Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized, placebo-controlled clinical trial with a 2-year open extension Journal of Bone and Mineral Research 17 2002 1057-1064
11. E. McCloskey P. Selby M. Davies et al. Clodronate reduces vertebral fracture risk in women with postmenopausal osteoporosis: Results of a double-blind, placebo-controlled 3-year study Journal of Bone and Mineral Research 19 2004 728-736
12. Ch. Chesnut III A. Skag C. Christiansen et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis Journal of Bone and Mineral Research 2004 1241-1249
13. A. Cranney G. Wells A. Willan et al. Meta-analysis of alendronate for the treatment of postmenopausal women Endocrine Reviews 23 2002 508-516
14. A. Cranney P. Tugwell J. Adachi et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis Endocrine Reviews 23 2002 517-523
15. S.E. Papapoulos S.A. Quandt U.A. Liberman et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporosis International 16 2005 468-474
16. C.L.M. Cremers G. Pillai & S.E. Papapoulos Pharmacokinetics/ pharmacodynamics of bisphosphonates Clinical Pharmacokinetics 44 2005 551-570
17. S. Gonelli C. Cepollaro C. Pondrelli et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis Calcified Tissue International 65 1999 359-364
18. M.J. Seibel V. Naganathan I. Barton & A. Gauer Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate Journal of Bone and Mineral Research 19 2004 323-329
19. D.C. Bauer D.M. Black P. Garnero et al. Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: The fracture intervention trial Journal of Bone and Mineral Research 19 2004 1250-1258
20. P.H. Reitsma O.L.M. Bijvoet H. Verlinden-Ooms & L.J.A. Wee van der Plas Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate in rats Calcified Tissue International 32 1980 145-157
21. S.E. Papapoulos J.O. Landman O.L.M. Bijvoet et al. The use of bisphosphonates in the treatment of osteoporosis Bone 13 supplement 1 1992 S41-S49
22. H.G. Bone D. Hosking J.P. Devogelaer et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women The New England Journal of Medicine 350 2004 1189-1199
23. D.D. Mellstrom O.H. Sorensen S. Goemaers et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcified Tissue International 75 2004 462-468
24. R. Recker K. Ensrud S. Diem et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women Journal of Bone and Mineral Research 19 supplement 2 2004 S45
25. L.G. Ste-Marie E. Sod T. Johnson & A. Chines 5 years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis Calcified Tissue International 75 2004 459-476
26. D. Black A. Schwartz K. Ensrud et al. A 5 year randomized trial of the long-term efficacy and safety of alendronate: The FIT long-term extension (FLEX) Journal of Bone and Mineral Research 19 supplement 2 2004 S45
27. M.R. McClung R.D. Wasnich D.J. Hosking et al. Prevention of postmenopausal bone loss: Six-year results from the Early Postmenopausal Intervention Cohort Study Journal of Clinical Endocrinology and Metabolism 89 2004 4879-4885
28. R.D. Wasnich Y.Z. Bagger D.J. Hosking et al. Changes in bone mineral density and turnover after alendronate or estrogen withdrawal Menopause 11 2004 622-630
29. J.O. Landman N.A. Hamdy E.K. Pawels & S.E. Papapoulos Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate Journal of Clinical Endocrinology and Metabolism 80 1995 3465-3468
30. J.A. Cramer M.M. Amonkar A. Hebborn & N. Suppapanya Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? Journal of Bone and Mineral Research 19 supplement 1 2004 S448
31. N. Watts I.B. Barton W.P. Olszynski et al. Treatment discontinuation effects on bone turnover and BMD with risedronate Bone 34 supplement 1 2004 s99
32. C. Rosen M. Hochberg S. Bonnick et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized, double-blind study Journal of Bone and Mineral Research 20 2005 141-151